Central Dermatology, PC

St Louis, Missouri 63117

0 studies enrolling now · 23 studies all time

What they study most

Acne, Acne Vulgaris, Atopic Dermatitis, Cutaneous Lupus Erythematosus, Papulopustular Rosacea (PPR), Plaque Psoriasis, Psoriasis, Rosacea

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of LY3471851 in Participants With Psoriasis — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam — Completed
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) — Completed
• Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea — Completed
• Phase 3 Papulopustular Rosacea Study — Completed
• Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1% — Completed
• Epiduo Pediatric Acne Study — Completed
• Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris — Completed
• Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea — Completed
• Topical CP-690,550 For Chronic Plaque Psoriasis — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis — Completed
• A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) — Completed
• A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis — Completed